A comparison of bilateral breast cancers in BRCA carriers

Jeffrey N. Weitzel, Mark Robson, Barbara Pasini, Siranoush Manoukian, Dominique Stoppa-Lyonnet, Henry T. Lynch, Jane McLennan, William D. Foulkes, Teresa Wagner, Nadine Tung, Parviz Ghadirian, Olufunmilayo Olopade, Claudine Isaacs, Charmaine Kim-Sing, Pal Møller, Susan L. Neuhausen, Kelly Metcalfe, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Women with breast cancer and a BRCA mutation have a high risk of developing a contralateral breast cancer. It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown. Purpose: To determine the degree of concordance of estrogen receptor (ER) status, tumor grade, and histology in tumors from women with bilateral breast cancer and a BRCA mutation. Subjects and Methods: Women with a history of bilateral invasive breast cancers were selected from an international registry of women with BRCA1 or BRCA2 mutations. Medical records were reviewed to document the characteristics of each cancer and the treatments received. Results: Data were available for 286 women with bilateral breast cancer and a BRCA mutation (211 BRCA1; 75 BRCA2). The mean interval between first and second tumor was 5.1 years. The two tumors were concordant more often than expected for ER status (P <0.0001) and for grade (P <0.0001), but not for histology (P = 0.55). The ER status of the first tumor was highly predictive of the ER status of the second tumor (odds ratio, 8.7; 95% confidence interval, 3.5-21.5; P <0.0001). Neither age, menopausal status, oophorectomy nor tamoxif en use was predictive of the ER status of the second tumor. Conclusions: There is strong concordance in ER status and tumor grade between independent primary breast tumors in women with a BRCA mutation. The excess concordance may be due to common risk factors, genetic variation, or the existence of a preneoplastic lesion that is common to both tumors.

Original languageEnglish
Pages (from-to)1534-1538
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume14
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

Breast Neoplasms
Estrogen Receptors
Neoplasms
Mutation
Histology
Ovariectomy
Medical Records
Registries
Odds Ratio
Hormones
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Weitzel, J. N., Robson, M., Pasini, B., Manoukian, S., Stoppa-Lyonnet, D., Lynch, H. T., ... Narod, S. A. (2005). A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiology Biomarkers and Prevention, 14(6), 1534-1538. https://doi.org/10.1158/1055-9965.EPI-05-0070

A comparison of bilateral breast cancers in BRCA carriers. / Weitzel, Jeffrey N.; Robson, Mark; Pasini, Barbara; Manoukian, Siranoush; Stoppa-Lyonnet, Dominique; Lynch, Henry T.; McLennan, Jane; Foulkes, William D.; Wagner, Teresa; Tung, Nadine; Ghadirian, Parviz; Olopade, Olufunmilayo; Isaacs, Claudine; Kim-Sing, Charmaine; Møller, Pal; Neuhausen, Susan L.; Metcalfe, Kelly; Sun, Ping; Narod, Steven A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 14, No. 6, 06.2005, p. 1534-1538.

Research output: Contribution to journalArticle

Weitzel, JN, Robson, M, Pasini, B, Manoukian, S, Stoppa-Lyonnet, D, Lynch, HT, McLennan, J, Foulkes, WD, Wagner, T, Tung, N, Ghadirian, P, Olopade, O, Isaacs, C, Kim-Sing, C, Møller, P, Neuhausen, SL, Metcalfe, K, Sun, P & Narod, SA 2005, 'A comparison of bilateral breast cancers in BRCA carriers', Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 6, pp. 1534-1538. https://doi.org/10.1158/1055-9965.EPI-05-0070
Weitzel, Jeffrey N. ; Robson, Mark ; Pasini, Barbara ; Manoukian, Siranoush ; Stoppa-Lyonnet, Dominique ; Lynch, Henry T. ; McLennan, Jane ; Foulkes, William D. ; Wagner, Teresa ; Tung, Nadine ; Ghadirian, Parviz ; Olopade, Olufunmilayo ; Isaacs, Claudine ; Kim-Sing, Charmaine ; Møller, Pal ; Neuhausen, Susan L. ; Metcalfe, Kelly ; Sun, Ping ; Narod, Steven A. / A comparison of bilateral breast cancers in BRCA carriers. In: Cancer Epidemiology Biomarkers and Prevention. 2005 ; Vol. 14, No. 6. pp. 1534-1538.
@article{2b6e7592952b47ee88b05bf6d9177b65,
title = "A comparison of bilateral breast cancers in BRCA carriers",
abstract = "Background: Women with breast cancer and a BRCA mutation have a high risk of developing a contralateral breast cancer. It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown. Purpose: To determine the degree of concordance of estrogen receptor (ER) status, tumor grade, and histology in tumors from women with bilateral breast cancer and a BRCA mutation. Subjects and Methods: Women with a history of bilateral invasive breast cancers were selected from an international registry of women with BRCA1 or BRCA2 mutations. Medical records were reviewed to document the characteristics of each cancer and the treatments received. Results: Data were available for 286 women with bilateral breast cancer and a BRCA mutation (211 BRCA1; 75 BRCA2). The mean interval between first and second tumor was 5.1 years. The two tumors were concordant more often than expected for ER status (P <0.0001) and for grade (P <0.0001), but not for histology (P = 0.55). The ER status of the first tumor was highly predictive of the ER status of the second tumor (odds ratio, 8.7; 95{\%} confidence interval, 3.5-21.5; P <0.0001). Neither age, menopausal status, oophorectomy nor tamoxif en use was predictive of the ER status of the second tumor. Conclusions: There is strong concordance in ER status and tumor grade between independent primary breast tumors in women with a BRCA mutation. The excess concordance may be due to common risk factors, genetic variation, or the existence of a preneoplastic lesion that is common to both tumors.",
author = "Weitzel, {Jeffrey N.} and Mark Robson and Barbara Pasini and Siranoush Manoukian and Dominique Stoppa-Lyonnet and Lynch, {Henry T.} and Jane McLennan and Foulkes, {William D.} and Teresa Wagner and Nadine Tung and Parviz Ghadirian and Olufunmilayo Olopade and Claudine Isaacs and Charmaine Kim-Sing and Pal M{\o}ller and Neuhausen, {Susan L.} and Kelly Metcalfe and Ping Sun and Narod, {Steven A.}",
year = "2005",
month = "6",
doi = "10.1158/1055-9965.EPI-05-0070",
language = "English",
volume = "14",
pages = "1534--1538",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - A comparison of bilateral breast cancers in BRCA carriers

AU - Weitzel, Jeffrey N.

AU - Robson, Mark

AU - Pasini, Barbara

AU - Manoukian, Siranoush

AU - Stoppa-Lyonnet, Dominique

AU - Lynch, Henry T.

AU - McLennan, Jane

AU - Foulkes, William D.

AU - Wagner, Teresa

AU - Tung, Nadine

AU - Ghadirian, Parviz

AU - Olopade, Olufunmilayo

AU - Isaacs, Claudine

AU - Kim-Sing, Charmaine

AU - Møller, Pal

AU - Neuhausen, Susan L.

AU - Metcalfe, Kelly

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2005/6

Y1 - 2005/6

N2 - Background: Women with breast cancer and a BRCA mutation have a high risk of developing a contralateral breast cancer. It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown. Purpose: To determine the degree of concordance of estrogen receptor (ER) status, tumor grade, and histology in tumors from women with bilateral breast cancer and a BRCA mutation. Subjects and Methods: Women with a history of bilateral invasive breast cancers were selected from an international registry of women with BRCA1 or BRCA2 mutations. Medical records were reviewed to document the characteristics of each cancer and the treatments received. Results: Data were available for 286 women with bilateral breast cancer and a BRCA mutation (211 BRCA1; 75 BRCA2). The mean interval between first and second tumor was 5.1 years. The two tumors were concordant more often than expected for ER status (P <0.0001) and for grade (P <0.0001), but not for histology (P = 0.55). The ER status of the first tumor was highly predictive of the ER status of the second tumor (odds ratio, 8.7; 95% confidence interval, 3.5-21.5; P <0.0001). Neither age, menopausal status, oophorectomy nor tamoxif en use was predictive of the ER status of the second tumor. Conclusions: There is strong concordance in ER status and tumor grade between independent primary breast tumors in women with a BRCA mutation. The excess concordance may be due to common risk factors, genetic variation, or the existence of a preneoplastic lesion that is common to both tumors.

AB - Background: Women with breast cancer and a BRCA mutation have a high risk of developing a contralateral breast cancer. It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown. Purpose: To determine the degree of concordance of estrogen receptor (ER) status, tumor grade, and histology in tumors from women with bilateral breast cancer and a BRCA mutation. Subjects and Methods: Women with a history of bilateral invasive breast cancers were selected from an international registry of women with BRCA1 or BRCA2 mutations. Medical records were reviewed to document the characteristics of each cancer and the treatments received. Results: Data were available for 286 women with bilateral breast cancer and a BRCA mutation (211 BRCA1; 75 BRCA2). The mean interval between first and second tumor was 5.1 years. The two tumors were concordant more often than expected for ER status (P <0.0001) and for grade (P <0.0001), but not for histology (P = 0.55). The ER status of the first tumor was highly predictive of the ER status of the second tumor (odds ratio, 8.7; 95% confidence interval, 3.5-21.5; P <0.0001). Neither age, menopausal status, oophorectomy nor tamoxif en use was predictive of the ER status of the second tumor. Conclusions: There is strong concordance in ER status and tumor grade between independent primary breast tumors in women with a BRCA mutation. The excess concordance may be due to common risk factors, genetic variation, or the existence of a preneoplastic lesion that is common to both tumors.

UR - http://www.scopus.com/inward/record.url?scp=20444387248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444387248&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-05-0070

DO - 10.1158/1055-9965.EPI-05-0070

M3 - Article

VL - 14

SP - 1534

EP - 1538

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -